Methods for treatment of and prophylaxis against inflammatory disorders
An isolated and purified peptide, neonatal NET-inhibitory Factor (nNIF), is disclosed. Methods for treatment of and prophylaxis against inflammatory disorders are also disclosed, including methods of treatment of and prophylaxis against inflammatory disorders comprising administering NET-inhibitory peptides (NIPs), which may be a nNIF, a pharmaceutically acceptable salt of a nNIF, a nNIF analog, a pharmaceutically acceptable salt of a nNIF analog, a nNIF-Related Peptide (nNRP), including the nNRP, Cancer-Associated SCM-Recognition, Immune Defense Suppression, and Serine Protease Protection Peptide (CRISPP), a pharmaceutically acceptable salt of a nNRP, a nNRP analog, or a pharmaceutically acceptable salt of a nNRP analog, to an individual.
1. A method for treating neutrophil extracellular trap (NET) mediated inflammatory tissue damage in a patient, comprising:
administering to the patient an effective amount of a pharmaceutical composition comprising a peptide consisting of the amino acid sequence of SEQ ID NO:4 having an amino acid substitution and a pharmaceutically acceptable carrier to reduce a pathological effect or symptom of the NET-mediated inflammatory disorder.
2. The method of claim 1 , wherein the pharmaceutical composition substantially inhibits NET-mediated inflammatory tissue damage.
3. The method of claim 1 , wherein the patient is human.
4. A method for inhibiting NET formation in a patient, comprising:
administering to the patient an effective amount of a pharmaceutical composition comprising a peptide consisting of the amino acid sequence of SEQ ID NO:4 having an amino acid substitution and a pharmaceutically acceptable carrier to substantially inhibit NET formation.
5. The method of claim 4 , wherein the NET formation is stimulated by a virus selected from at least one of a hemorrhagic fever virus, a Filovirus, an arenavirus, a hantavirus, a flavivirus, dengue virus, yellow fever virus, or HIV-1.
6. The method of claim 4 , wherein the NET formation is stimulated by a bacterium selected from at least one of a Bacillus species, an Escherichia species, a Francisella species, a Staphylococcus species, a Streptococcus species, or a Yersinia species.
7. The method of claim 4 , wherein the patient is human.
8. A pharmaceutical composition, comprising:
a peptide consisting of the amino acid sequence of SEQ ID NO:4 having an amino acid substitution; and
a pharmaceutically acceptable carrier.
9. The method of claim 1 , wherein at least one amino acid of the peptide is bound to a chemical modifier, and
wherein the chemical modifier is selected from at least one of a lipid, a polyethylene glycol (PEG), or a saccharide.
10. The method of claim 1 , wherein the peptide does not globally depress polymorphonuclear leukocyte (PMN) function.
11. The method of claim 1 , wherein the peptide does not substantially inhibit one or more activities of a polymorphonuclear leukocyte (PMN) selected from the group consisting of chemotaxis, chemokine synthesis and secretion, cytokine synthesis and secretion, extracellular bacterial killing, intracellular bacterial killing, phagocytosis, and reactive oxygen species (ROS) generation.
12. The method of claim 1 , wherein the peptide is present in an amount effective to substantially inhibit neutrophil extracellular trap (NET) formation.
13. The method of claim 1 , wherein the NET formation is stimulated by at least one of a bacterium, a fungus, a parasite, or a virus.
14. The method of claim 1 , wherein the amino acid substitution is a nonconservative substitution.
15. The method of claim 4 , wherein the amino acid substitution is a nonconservative substitution.